IRCT20201219049765N1招募中3 期
Comparison of the effect of liposomal form of pistachio kernel oil and placebo on the level of some inflammatory and anti-inflammatory agents as well as their receptors in mononuclear cells in peripheral blood and change in the severity of clinical symptoms in women with multiple sclerosis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 51 years（—）
- 性别
- Female
入选标准
- •Women aged 18 to 51 years
- •Definite diagnosis of multiple sclerosis with a descriptive measure of disability rate between 1 to 3
排除标准
- •Taking corticosteroids during the study
- •Pregnancy and lactation
- •Active cardiovascular disease, liver disease, gastrointestinal disease, patients with Helicobacter pylori positive test, kidney disease, diabetes mellitus, respiratory disease and autoimmune diseases
- •Take multivitamin, mineral, antioxidant and pistachio kernel supplements during the 30 days before the study
研究者
相似试验
尚未招募
不适用
To compare the effectiveness between liposomal iron and conventional iron in the treatment of iron deficiency anaemia in children aged 6months-5years.CTRI/2024/06/068445Dr Suresh R
尚未招募
4 期
Effectiveness of liposomal and ferrous iron in the treatment of iron deficiencyIRCT20151020024625N17Semnan University of Medical Sciences60
进行中（未招募）
不适用
Evalutation of the effects of non pegylated liposomial doxorubicin MYOCET on the reduction of skin and cardiac toxicity in platinum resistant ovarian and endometrial cancer patients . A phase II studysecond line treatment in platinum resistant ovarian and endometrial cancerMedDRA version: 6.1Level: PTClassification code 10033128EUCTR2005-002540-26-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
2 期
Comparison the therapeutic effects of liposomal tranexamic acid form and conventional form of Hydroquinone on melasma patientsMelasma.MelasmaIRCT201403173862N10Research Council of Mashhad University of Medical Sciences30
招募中
2 期
A randomized phase II study comparing liposomal irinotecan + fluorouracil + levofolinate to FOLFIRINOX as second-line chemotherapy for pancreatic cancer (NUPAT-09 trial)D021441Pancreatic cancerJPRN-jRCT1041200082Maeda Osamu40